All In Biotech

Drug Trial Radar · NCT05071300

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

151

Actual

Start

Jan 4, 2022

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Oct 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).

Conditions

  • Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Interventions

  • EplontersenDrug

    Eplontersen will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Platelet CountTime frame: Baseline to Week 181
  2. Number of Participants With Clinically Significant Changes From Baseline in Renal FunctionTime frame: Baseline to Week 181
  3. Number of Participants with Clinically Significant Changes from Baseline in TransaminasesTime frame: Baseline to Week 181
  4. Change From Baseline in Adverse EventsTime frame: Baseline to Week 181
  5. Change From Baseline in Number of Concomitant Medications UsedTime frame: Baseline to Week 181
  6. Number of Participants With Clinically Significant Changes From Baseline in Vital SignsTime frame: Baseline to Week 181
  7. Change From Baseline in Body WeightTime frame: Baseline to Week 181
  8. Number of Participants With Clinically Significant Changes From Baseline in Physical Examination FindingsTime frame: Baseline to Week 181
  9. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory TestsTime frame: Baseline to Week 181
  10. Number of Participants With Clinically Significant Changes From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline to Week 181
  11. Number of Participants With Clinically Significant Changes From Baseline in Thyroid Panel TestsTime frame: Baseline to Week 181
  12. Number of Participants With Clinically Significant Changes From Baseline in Coagulation TestsTime frame: Baseline to Week 181
  13. Number of Participants With Clinically Significant Changes From Baseline in Inflammatory Panel TestsTime frame: Baseline to Week 181
  14. Number of Participants With Clinically Significant Changes From Baseline in Complement and Immunogenicity TestsTime frame: Baseline to Week 181

Locations

33 sites in 13 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • Indiana University Health University Hospital

    Indianapolis, Indiana

  • Johns Hopkins University Neurology Research Office

    Baltimore, Maryland

  • Boston University School of Medicine

    Boston, Massachusetts

  • The Neurological Institute of New York

    New York, New York

  • University of North Carolina Hospitals - Neurology Clinic

    Chapel Hill, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • University of Washington Medical Center

    Seattle, Washington

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Instituto Fleni

    Buenos Aires, Argentina

  • Hospital El Cruce

    San Juan Bautista, Argentina

  • Perron Institute for Neurological and Translational Science

    Murdoch, Western Australia, Australia

  • Universidade Estadual de Campinas

    Campinas, Brazil

  • Instituto de Neurologia de Curitiba

    Curitiba, Brazil

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto

    São Paulo, Brazil

  • Hospital Universitario Clementino Fraga Filho

    Botafogo, Rio de Janeiro, Brazil

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • The Cyprus Institute of Neurology and Genetics

    Égkomi, Cyprus

  • Hôpital de la Timone

    Marseille, France

  • Centre Hospitalier Universitaire de Toulouse

    Toulouse, Haute-Garonne, France

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Carlo Besta

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria

    Lisbon, Portugal

  • Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio

    Porto, Portugal

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Son Llàtzer

    Palma de Mallorca, Spain

  • Norrlands Universitetssjukhus

    Umeå, Sweden

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital

    Taoyuan, Taiwan

  • Istanbul Üniversitesi - Istanbul Tip Fakültesi

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.